FDA Says 'No' to Resubmission of Antiarrhythmic Drug

06:15 EDT 22 Aug 2017 | PharmPro

Cardiome provides U.S. regulatory update for Brinavess. The FDA indicated that data supplied was not compelling enough to support a resubmission of the company's New Drug Application, despite acceptance elsewhere around the world.
Contributed Author: 
Cardiome Pharma Corp.

Original Article: FDA Says 'No' to Resubmission of Antiarrhythmic Drug


More From BioPortfolio on "FDA Says 'No' to Resubmission of Antiarrhythmic Drug"

Quick Search


Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...